 |
|
Use and Effectiveness of Transdermal Nicotine in Primary Care Settings-Reply
K. Michael Cummings, MPH, PhD;
Michael A. Zevon, PhD
Roswell Park Cancer Institute Buffalo, NY
Carlos R. Jaén, MD, PhD
State University of New York—Buffalo
Arch Fam Med. 1995;4(4):304-305.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In reply
Dr White raises an interesting question regarding the impact of media advertising on the use of nicotine skin patches in his letter.1 In the advertising business, it is often said that, "... without advertising, a terrible thing happens—nothing." When the Food and Drug Administration approved the marketing of prescription nicotine patches in late 1991, patch manufacturers launched a multimillion-dollar advertising campaign to alert consumers to the availability of this new stop-smoking aid. Advertising contributed to the ordering of over 7 million prescriptions for the patch in 1992.2
As Dr White suggests, many of those who may have responded to the advertising for the nicotine patch were seeking a quick fix to help them break their addiction to nicotine. Unfortunately, the patch is not a cure for nicotine addiction. While our study of nicotine patch users suggests that the patch can help a person who smokes to quit, the most
. . . [Full Text PDF of this Article]
|
